Compare BioNano Genomics Inc (BNGO) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.75. The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | EMB | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Fixed Income |
52-Week High | $4.92 | $97.74 |
52-Week Low | $1.09 | $91.52 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
EMB trades at $95.38, down 0.64% on the day, with a bearish technical signal from moving averages and oscillators. The stock shows oversold conditions with a 6-day RSI at 29.09, while recent corporate actions include scheduled dividends for mid-2026. News coverage highlights emerging market bond risks and Federal Reserve policy impacts on similar ETFs.
The outlook remains cautious due to technical weakness and macro risks in emerging markets. Investment opportunity lies in potential oversold rebound, but risks include sovereign default exposure and interest rate sensitivity. Investor sentiment is mixed amid global fixed income volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
